B. Riley analyst Kalpit Patel lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $28 from $40 and keeps a Buy rating on the shares. The firm cites higher discount rates and muted investor interest in early-stage assets for the price target decrease. B. Riley remains confident in the investment case for CRB-701, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals price target lowered to $58 from $65 at RBC Capital
- Corbus Pharmaceuticals price target lowered to $56 from $60 at Oppenheimer
- Corbus Pharmaceuticals price target lowered to $40 from $50 at H.C. Wainwright
- Corbus Pharmaceuticals Advances Clinical Pipeline Amid Q1 Loss
- Corbus Pharmaceuticals Receives FDA Fast Track Designation